Cost-Effectiveness of Length of Stay of Intravenous Aminophylline and Nebulized Salbutamol in Asthma Exacerbations
DOI:
https://doi.org/10.25026/jtpc.v8i1.435Keywords:
asthma, salbutamol, aminophylline, outcome, costAbstract
Asthma is a heterogeneous disease which is also one of the major health problems in the world. Uncontrolled asthma symptoms will exacerbate asthma, which is the biggest cause of the patient into the ER. Salbutamol is a bronchodilator that belonged to the short-acting beta-2 agonist (SABA), which is an obligatory choice in the management of asthma exacerbations. Unlike the aminophylline group in Indonesia which is still often used widely and rarely appear in the side effects of its use. The main objective of this study was to evaluate the cost-effectiveness of nebulized salbutamol versus intravenous aminophylline for reduction in asthma symptoms, improvement in lung function, and a long hospital stay. The study involved 57 adults asthma exacerbation patients without complication who received treatment in the ER, were studied by using quasi-experimental methods in this study cost-effectiveness analysis to compare intravenous aminophylline (n:27) versus nebulized salbutamol (n:30) therapy to determine the most cost-effective. Intravenous aminophylline therapy was more cost-effective than nebulized salbutamol in reducing the symptoms of asthma and PEF value improvement. Clinical outcome of the length of hospital stay outcome both had the same effective, and cost analysis results showed intravenous aminophylline (US$5.38) cheaper than nebulized salbutamol (US$5.71). intravenous aminophylline was more effective in reducing asthma symptoms than nebulized salbutamol (Pvalue=0.001). Meanwhile, the average decrease in lung function intravenous aminophylline than nebulized salbutamol, although not significantly different (Pvalue=0.507). Aminophylline therapy was more cost-effective in reducing asthma symptoms and improvement in lung function compared nebulized salbutamol in exacerbations asthma patients. But cost-effectiveness researchers need to measure substance abuse outcomes in terms of Quality-Adjusted Life Years (QALY), as this will make their findings more relevant to the development of treatment policy.
Downloads
References
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management & Prevention (Update), USA. 2019.
Bush, A. (2019). Pathophysiological Mechanisms of Asthma. Front Pediatr, 7(68):1–17.
Kementerian Kesehatan. Keputusan Menteri Kesehatan Republik Indonesia, Nomor 312/MENKES/SK/IX/2015, tentang Daftar Obat Essensial 2015, Jakarta, Kementerian Kesehatan Republik Indonesia.
Kementerian Kesehatan. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.02.02/MENKES/523/2015, tentang Formularium Nasional, Jakarta, Kementerian Kesehatan Republik Indonesia.
Travers, A.H., Jones, A.P., Camargo, C.A., Milan, S.J., and Rowe, B.H. (2012). Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database Syst Rev, 12:CD010256.
Roberts, G., Newsom, D., Gomez, K., Raffles, A., Saglani, S., and Begent, J. (2003). Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial. Thorax, 58:306–10.
Tilley, S.L. (2011). Methylxanthines in asthma. Handb Exp Pharmacol, 200:439?56.
Barnes, P.J. (2010). Theophylline. Pharmaceuticals (Basel), 3(3):725?47.
Lorensia, A., Wahjuningsih, E., Canggih, B., and Lisiska, N. (2011). Pharmacist’s Strategies in Treating Asthma Bronchiale Outpatient. Jurnal of Tropical Pharmacy and Chemistry, 1(3):177–91.
Lorensia, A., Wahjuningsih, E., and Supriadi. (2012). Safety of Aminophylline for Asthma Therapy in Delta Surya Hospital at Sidoarjo. Indonesia journal of Clinical Pharmacy, 1(4):154–61.
Lorensia, A., Canggih, B., and Wijaya, R.I. (2013). Analysis of Adverse Drug Reactions in Asthma Patients in a Hospital, Surabaya. Jurnal Farmasi Indonesia, 6(3):142–50.
Lorensia, A., Wahyudi, M., Yudiarso, A., and Kurnia, S.E.D. (2020). Effect of illness perception on improving asthma symptoms with omega-3 fish oil therapy: Pre-post design. Journal of Applied Pharmaceutical Science, 10(6):62–71.
Lorensia, A., Ikawati, Z., Andayani, T.M., Maranatha, D., and Wahjudi, M. (2016). Comparison of Electrolyte Disturbance of Using Intravenous Aminophylline Versus Nebulization Salbutamol for Exacerbation Asthma in Surabaya, Indonesia. International Journal of Pharmaceutical and Clinical Research, 8(4):221–8.
Dalabih, A., Harris, Z.L., Bondi, S.A., and Arnold, D.H. (2012). Contemporary aminophylline use for status asthmaticus in pediatric ICUs. Chest, 141(4):1122–3.
Mahemuti, G., Zhang, H., Li, J., Tieliwaerdi, N., and Ren, L. (2018). Efficacy and side effects of intravenous theophylline in acute asthma: a systematic review and meta-analysis. Drug Des Devel Ther, 12:99?120.
Saint, G.L., Semple, M.G., Sinha, I., and Hawcutt, D.B. (2018). Optimizing the Dosing of Intravenous Theophylline in Acute Severe Asthma in Children. Paediatr Drugs, 20(3):209?14.
Cooney, L., Sinha, I., and Hawcutt, D. (2016). Aminophylline Dosage In Asthma Exacerbations in Children: A Systematic Review. PLoS One, 11(8):e0159965.
Lorensia, A., Ikawati, Z., Andayani, T.M., Maranatha, D., and Wahyudi, M. (2019). CYP1A2 Gene Polymorphism and Theophylline Level in Asthma. The Indonesian Biomedical Journal, 11(1):63–9.
Fenech, A.G., Grech, G. (2011). Pharmacogenetics: Where do we stand?. Journal of the Malta College of Pharmacy Practice, 11:25–33.
Tse, S.M., Tantisira, K., and Weiss, S.T. (2011). The Pharmacogenetics and Pharmacogenomics of Asthma Therapy. Pharmacogenomics Journal, 11(6):383?92.
Uslu, A., Ogus, C., Ozdemir, T., Bilgen, T., Tosun, O., and Keser, I. (2010). The effect of CYP1A2 gene polymorphisms on Theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients. Biochemistry and Molecular Biology reports, 43(8):530?4.
Obase, Y., Shimoda, T., Kawano, T., Saeki, S., Tomari, S.Y., Mitsuta-Izaki, K., Matsuse, H., Kinoshita, M., and Kohno, S. (2003). Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clinical Pharmacology and Therapeutics, 73(5):468?74.
Roden, D.M., Wilke, R.A., Kroemer, H.K., and Stein, C.M. (2011). Pharmacogenomics: the genetics of variable drug responses. Circulation, 123(15):1661?70.
Sanchez-Ibarra, H.E., Reyes-Cortes, L.M., Jiang, X.L., Luna-Aguirre, C.M., Aguirre-Trevino, D., Morales-Alvarado, I.A.M., Leon-Cachon, R.B., Lavalle-Gonzalez, F., Morcos, F., and Barrera-Saldana, H.A. (2018). Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus. Front Pharmacol, 9(320):1?11.
Queljoe, D.D., Wahjudi, M., Erdiansyah, M., Suryadinata, R.V., and Lorensia, A. (2014). Pilot Study on Genetic Polymorphisms CYP1A2*1F on Asthma Patients and Nonasthma in Indonesia. Indonesia journal of Clinical Pharmacy, 4(1):8?16.
SNPedia. 2016, rs762551. [ONLINE] Available at: https://www.snpedia.com/index.php/Rs762551 [Accessed 12 Desember 2020].
Nunes, C., Pereira, A.M., and Morais-Almeida, M. (2017). Asthma costs and social impact. Asthma Res Pract, 3(1):1?11.
Souiotis, K., Kousoulakou, H., Hillas, G., Bakakos, P., Toumbis, M., Loukides, S., and Vassilakopoulos, T. (2017). Direct and Indirect Costs of Asthma Management in Greece: An Expert Panel Approach. Front. Public Health, 5(67):1?6.
Cookson, R., Mirelman, A.J., Griffin, S., Asaria, M., Dawkins, B., Norheim, O.F., Verguet, S., and Culyer, A. (2017). Using Cost-Effectiveness Analysis to Address Health Equity Concerns. Value Health, 20(2):206–12.
Thomas, R., Chalkidou, K. Cost–effectiveness analysis. 2016. In: Cylus J, Papanicolas I, Smith PC, editors. Health system efficiency: How to make measurement matter for policy and management. Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2016. (Health Policy Series, No. 46.) 6. [ONLINE] Available at: https://www.ncbi.nlm.nih.gov/books/NBK436886/. [Accessed 12 Desember 2020].
Savitz, L.A., Savitz, S.T. (2016). Can delivery systems use cost-effectiveness analysis to reduce healthcare costs and improve value?. F1000Res, 5(F1000):1?6.
Chipps, B.E., Foggs, M.B. (2015). Asthma Management and the Allergist: Better Outcomes at Lower Cost. American College of Allergy. [ONLINE] Available at: https://college.acaai.org/sites/default/files/Asthma%20management.pdf. [Accessed 12 Desember 2020].
Lorensia, A., Wijaya, R.I., and Canggih, B. (2013). Cost-Effectiveness Study related to Inpatient Selection of Bronchial Asthma Medication at a Private Hospital in Surabaya. Jurnal Ilmiah Sains & Teknologi, 7(1):56–63.
Singh, A.S., Masuku, M.B. (2014). Sampling Techniques & Determination of Sample Size in Applied Statistics Research: An Overview. International Journal of Economics, Commerce and Management, 2(11):1?22.
National Asthma Council Australia. 2006. Asthma Handbook: Version 2.0 Management Adults. [ONLINE] Available at: https://www.asthmahandbook.org.au/static/files/Australian-Asthma-Handbook-v2.0-Management-%E2%80%93-Adults.pdf. [Accessed 1 Maret 2021].
Fong, N. (2011). Aminophylline/Theophylline: Loading and maintenance dose, NHS Trust: East Lancashire Hospitals. 2011
Barnard, A. (2005). Management of an Acute Asthma Attack, Australian Family Physician, 34(7):531?4.
Luo, Z., Liu, E., Luo, J., Li, S., Zeng, F., Yang, X., and Fu, Z. (2010). Nebulized hypertonic saline/salbutamol solution treatment in hospitalized children with mild to moderate bronchiolitis. Pediatr Int, 52(2):199–202.
Kankaanranta, H., Kauppi, P., Tuomisto, L.E., and Ilmarinen, P. (2016). Emerging Comorbidities in Adult Asthma: Risks, Clinical Associations, and Mechanisms. Mediators of Inflammation, 3690628:1–23.
Veenendaal, M., Westerik, J.A.M., Bemt, L.V.D., Kocks, J.W.H., Bischoff, E.W., and Schermer, T.R. (2019). Age- and sex-specific prevalence of chronic comorbidity in adult patients with asthma: A real-life study. NPJ Prim Care Respir Med, 29(14):1?7.
Mahdavian, M., Power, B.H., Asghari, S., Pike, J.C. (2018). Effects of Comorbidities on Asthma Hospitalization and Mortality Rates: A Systematic Review. Can Respir J, 6460379:1–7.
Lorensia, A., Wahyudi, M., Yudiarso, A., Kurnia, S.E.D. (2020). Effect of illness perception on improving asthma symptoms with omega-3 fish oil therapy: Pre-post design. Journal of Applied Pharmaceutical Science, 10(6):62–71.
Niimi, A. (2011). Cough and Asthma. Curr Respir Med Rev, 7(1):47–54.
Morjaria, J.B., Rigby, A.S., Morice, A.L. (2017). Asthma phenotypes: do cough and wheeze predict exacerbations in persistent asthma?. European Respiratory Journal, 50(1701366):1–9.
Munro, A., Jacobs, M. (2004). Is intravenous aminophylline better than intravenous salbutamol in the treatment of moderate to severe asthma?. Emerg Med J, 21:78?80.
Lorensia, A., Wahjudi, M., Yudiarso, A., Suryadinata, R.V., and Ratnasari, R. (2020). Pilot Study of Lung Function Improvement in Peak Expiratory Flow (PEF) Value Using Fish Oil Containing Omega-3 Therapy in Asthma. Global Medical & Health Communication, 8(3):211–8.
Hua, J., Zhang, W., Cao, H.F., Du, C.L., Ma, J.Y., Zuo, Y.H., and Zhang, J. (2020). Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial. BMJ Open, 10(e034804):1–9.
Tattersfield, A.E., Postma, D.S., Barnes, P.J., Svensson, K., Bauer, C.A., O’Byrne, P.M., Löfdahl, C.G., Pauwels, R.A., Ullman, A. (1999). Exacerbations of asthma: a descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med, 160:594?9.
Burkhart, P.V., Rayens, M.K., and Oakley, M.G. (2012). Effect of Peak Flow Monitoring on Child Asthma Quality of Life. J Pediatr Nurs, 27(1):18–25.
Turner, M.O., Taylor, D., Bennertt, R., Fitzgerald, J.M. (1998). A Randomized Trial Comparing Peak Expiratory Flow and Symptom Self-management Plans for Patients with Asthma Attending a Primary Care Clinic. American Journal of Respiratory and Critical Care Medicine, 157(2):540?6.
Littenberg, B. (1988). Aminophylline Treatment in Severe, Acute Asthma a Meta-analysis. Journal of the American Medical Association (JAMA), 259(11):1678–84.
Hartnett, B.J.S., Marlin, G.E. (1976). Comparison of oral theophylline and salbutamol by inhalation in asthmatic patients. Br J Clin Pharmacol, 3(4):591–4.
Davies, B., Brooks, G., and Devoy, M. (1998). The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respiratory Medicine, 92(2):256–63.
Dawson, K.P., Fergusson, D.M. (1982). Effects of oral theophylline and oral salbutamol in the treatment of asthma. Archives of Disease in Childhood, 57:674–6.
Nakano, J., Yano, T., Yamamura, K., Yoshihara, H., Ohbayashi, O., Yamashita, N., and Ohta, K. (2006). Aminophilline suppress the release of chemical mediators in treatment of acute asthma. Respiratory Medicine, 100(3):542?50.
Okour, A.M., Saadeh, R.A., Hijazi, M.H., Khalaileh, H.E.A., and Alfaqih, M.A. (2019). Socioeconomic status, perceptions and obesity among adolescents in Jordan. Pan Afr Med J, 34(148):1?9.
Gradidge, P.J.L., Norris, S.A., Munthali, R. et al. (2018). Influence of socioeconomic status on changes in body size and physical activity in ageing black South African women. Eur Rev Aging Phys Act, 15(6):1–9.
PERMENKES (Peraturan Menteri Kesehatan), Nomor 27 (2014), tentang Petunjuk Teknis Sistem Indonesian Case Base Groups (INA-CBGs), Jakarta, Kementerian Kesehatan Republik Indonesia.
PERMENKES (Peraturan Menteri Kesehatan), Nomor 59 (2014), tentang Standar Tarif Pelayanan Kesehatan Dalam Penyelenggaraan Program Jaminan Kesehatan, Jakarta, Kementerian Kesehatan Republik Indonesia.
Vezina, K., Chauhan, B.F., and Ducharme, F.M. (2014). Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database Syst Rev, 31(CD010283):1?49.
Lorensia, A., Bahari, F.K. (2020). Cost-Effectiveness Analysis between Salbutamol-Ipratropium Combination with Salbutamol in Asthma Attack. Jurnal Insan Farmasi Indonesia, 3(1):38–49.
Domínguez-Ortega, J., Phillips-Anglés, E., Barranco, P., and Quirce, S. (2015). Cost-effectiveness of asthma therapy: a comprehensive review. J Asthma. 52(6):529–37.
Andrew, A.L., Wong, K.A., Heine, D., Russell, W.S. (2012). A Cost-effectiveness Analysis of Dexamethasone Versus Prednisone in Pediatric Acute Asthma. Academic Emergency Medicine, 19(8):943?8.
Fuseini, H., Newcomb, D.C. (2017). Mechanisms driving gender differences in asthma. Curr Allergy Asthma Rep, 17(3):19.
Yamauchi, K., Ogasawara, M. (2019). The Role of Histamine in the Pathophysiology of Asthma and the Clinical Efficacy of Antihistamines in Asthma Therapy. Int J Mol Sci, 20(1733):1?16.
Church, M.K. (2017). Allergy, Histamine and Antihistamines. Handb Exp Pharmacol, 241:321–31.
Billington, C.K., Ojo, O.O., Penn, R.B., and Ito, S. (2013). cAMP regulation of airway smooth muscle function. Pulm Pharmacol Ther, 26(1):112?20.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Tropical Pharmacy and Chemistry
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
